Company intelligence / Profile preview

LEAF4Life

Ownership: Private
Employees: ~249
Development stage: Phase 3

Overview

LEAF-4L6715 is being studied in three Phase 3 registrational studies in Europe for ARDS, Glioblastoma, and Sarcoma. The drug has received Compassionate Use Authorization in France for ARDS.

Therapeutic areas: PulmonologyCardiovascularOncologyNeurology
Modalities: Liposomal formulationTranscrocetin
Industry: Biotech

Drug pipeline

1 asset

liposomal transcrocetin

Beyond the preview

Go deeper on LEAF4Life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEAF4Life.

Explore the full profile